SRC and neoplasm: As AZD0424 did not sensitise DLD1 tumours that were inherently resistant to MEK inhibitor treatment, we next asked whether SRC inhibition could (re)sensitise cells that had acquired resistance to MEK inhibitors following prolonged treatment with trametinib.